Metformin - Sumitomo Dainippon Pharma

Drug Profile

Metformin - Sumitomo Dainippon Pharma

Alternative Names: Metformin hydrochloride- Dainippon Sumitomo Pharma; Metgluco; SMP-862

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Merck Sante
  • Developer Sumitomo Dainippon Pharma
  • Class Antihyperglycaemics; Biguanides; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 30 Oct 2013 Preregistration for Type-2 diabetes mellitus (in children) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top